论文部分内容阅读
目的探讨东菱精纯克栓酶治疗进展性脑梗死(PS)患者的临床疗效。方法选取2012年9月至2014年7月吉林省人民医院收治的90例进展性脑梗死患者作为研究对象,按随机数字表法将其分为试验组和对照组,各45例。对照组患者给予常规治疗,试验组患者在对照组基础上静脉滴注东菱精纯克栓酶,比较两组患者的临床疗效、脑功能缺损评分、血纤维蛋白原水平及不良反应发生情况。结果试验组患者的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后1周,试验组患者的血纤维蛋白原水平明显低于对照组,ESS评分明显高于对照组,差异均有统计学意义(均P<0.05);试验组患者的不良反应发生率明显低于对照组,差异有统计学意义(χ2=1.92,P<0.05)。结论东菱精纯克栓酶治疗早期PS患者临床疗效明显,可明显改善患者的神经功能缺损情况,降低血纤维蛋白原水平,且安全系数较高。
Objective To investigate the clinical effect of dianling Jing Ke thrombolytic enzyme in the treatment of patients with progressive cerebral infarction (PS). Methods Ninety patients with progressive cerebral infarction who were admitted to Jilin Provincial People’s Hospital from September 2012 to July 2014 were selected as study subjects and divided into experimental group and control group with 45 cases in each group according to random number table method. The patients in the control group were given routine treatment. The patients in the test group were given intravenous drip of Dongling Jingkejin enzyme on the basis of the control group. The clinical efficacy, brain function impairment score, fibrinogen level and adverse reactions of the two groups were compared. Results The total effective rate in the experimental group was significantly higher than that in the control group (P <0.05). One week after the treatment, the fibrinogen level in the experimental group was significantly lower than that in the control group, and the ESS score was significantly higher than that in the control group (P <0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, the difference was statistically significant (χ2 = 1.92, P <0.05). Conclusion Dongling Jing Ke thrombin enzyme treatment of early PS patients with significant clinical efficacy, can significantly improve the patient’s neurological deficit, lower fibrinogen levels, and a higher safety factor.